5-androstene 3 β ,17 α diol induces autophagic cell death of human breast cancer cells and enhances radiation cytotoxicity

Martin R. Graf¹, Wentao Jia², Tiffany Powell² and Roger M. Loria^{1,3*}

Correspondence: loria@vcu.edu

¹Departments of Microbiology and Immunology, Pathology and Emergency Medicine and the Massey Cancer Center, Virginia Commonwealth University, P.O. Box 980678, Richmond, VA, 23298-0678, USA.

²Department of Neurosurgery, Virginia Commonwealth University, P.O. Box 980631, Richmond, Virginia, 23298-0631, USA.

³Virginia and Commonwealth University Reanimation, Engineering Science Center (VCURES).

Abstract

Herein, we demonstrate that the steroid, 5-androstene 3 β ,17 α diol (17 α -AED) induced cell death in human breast cancer cells MCF-7, MDA-MB231, T47D and TTU-1 at clinically relevant levels. 17 α -AED treatment resulted in autophagic cell death without evidence of apoptosis in breast cancer cells revealed by increased cleavage of microtubule-associated protein-light chain 3 and the presence of acidic vesicular organelles in the absence of caspase 3, 8 or 9 activation and PARP processing. Increased phosphorylation of eukaryotic translational initiation factor 2 α (eIF2 α) was detected in treated MCF-7 cells and disruption of eIF2 α signaling reduced autophagic cell death in 17 α -AED treated MCF-7 cells. In breast cancer cell survival studies, 17 α -AED synergistically potentiated the cytotoxicity of radiation treatment. Collectively, 17 α -AED induces autophagic cell death in human breast tumors which is mediated, at least in part, by eIF2 α signaling and may have potential therapeutic value for the treatment of breast tumors.

Keywords: autophagy; androstene steroids; breast cancer; radio-sensitizer

Introduction

One out of eight women is reported to develop breast cancer and, despite recent therapeutic advances, it is the second leading cause of cancer deaths in the United States [1]. Invasive ductal cancer is the most common form of breast cancer and comprises ~75% of all cases [1]. Surgery followed by local-regional radiation therapy is considered the standard primary treatment and can be combined with adjuvant hormonal and/or chemotherapy. Tamoxifen is commonly used for breast tumors that are positive for the expression of the estrogen receptor (ER) or progesterone receptor which may be used in conjunction with aromatase inhibitors to increase efficacy or with chemotherapeutic agents such as cyclophosphamide, methotrexate or fluorouracil [2]. A recent advance in the treatment of this disease involves the use of trastuzumab (herceptin). Trastuzumab is a mAb specific for the human epidermal growth factor receptor 2 (Her-2/neu) which is expressed on ~25% of breast tumors and is used in combination with chemotherapy or radiation to specifically target Her-2/neu positive breast cancer cells [3,4]. Unfortunately, more than half of Her-2/neu positive breast tumors fail to respond or become resistant to trastuzumab-based chemotherapy [5]. Therefore, there is a need to investigate novel therapeutic agents for the

treatment of this cancer which may be used as a single agent or as adjuvant to enhance standard therapeutic modalities such as radiation.

Using an experimental mammary adenocarcinoma model, Schwartz *et al.* [6] demonstrated that the naturally occurring adrenal steroid dehydroepiandrosterone (DHEA) inhibited the spontaneous development of breast tumors. Additional studies showed that in vivo administration of DHEA suppresses the growth of human ZR75-1 breast tumor xenografts [7]. The steroid, 5-androstene 3 β ,17 α diol (17 α -AED), is a metabolite of DHEA and possesses significantly greater anti-tumor activity than DHEA [8]. We have shown that pharmacologically achievable concentrations of 17 α -AED inhibit the proliferation of human ER+ ZR75-1 and ER- MDA-MB231 human breast cancer cells, but cellular toxicity and associated cell death pathways were not analyzed [9].

Autophagy is generally considered a temporary cell survival response to starvation or a toxic environment in which cytosolic proteins are recycled; however, autophagy can also lead to type II programmed cell death [10-13]. For the initiation of autophagy, beclin-1 binds with class III phosphoinositol-3-kinase class III/p150 lipase [14,15]. Subsequently, an ubiquitin-like conjugation system involving Atg12-Atg5 and microtubule-associated

protein 1 light chain 3 (LC3) - phosphatidylethanolamine mediates the expansion of the pre-autophagosome membrane and the engulfment of organelles and protein constituents [10,14,15]. During this process LC3-I (18 kD) is converted to LC3-II (16 kD) and is incorporated into the membrane. At a later stage, autophagosome fuses with a lysosome to form an autolysosomes/acidic vesicular organelle (AVO) and the contents of the vesicle are degraded and recycled [10,14,15]. Previous investigations with 17 α -AED showed that tumor cell cytotoxicity can be mediated by the induction of either apoptotic or autophagic programmed cell death pathways depending on the etiological origin of the neoplasm. In this regard, 17 α -AED induces apoptosis in leukemias and autophagy malignant gliomas [16-18]. In this report, we demonstrate that 17 α -AED induces autophagic cell death in human breast tumors as evident by LC3 processing and the presence of AVOs, both biomarkers for autophagy, without caspase activation or poly (ADP-ribose) polymerase (PARP) cleavage. The neuro-steroid, 5-androstene 3 β ,17 α diol; induces endoplasmic reticulum stress and autophagy through PERK/eIF2 signaling in malignant glioma cells and transformed fibroblasts [19]. This report indicate that autophagy may be mediated by eukaryotic translational initiation factor-2 α (eIF2 α) signaling and that 17 α -AED can synergize with radiation to enhance breast tumor cell death.

Materials and methods

Cell lines and culture

Cells were cultured in RPMI 1640 supplemented with 5% fetal bovine serum as monolayers at 37°C, 5% CO₂ and 100% humidity and passed biweekly with trypsin in the absence of antibiotics. All culture reagents and supplements were obtained from Invitrogen Life Sciences (Carlsbad, CA). The MCF-7 breast adenocarcinoma cell line expresses ER α and a low level of ER β and the MDA-MB231 breast adenocarcinoma cell line is ER α negative, expresses a non-functional, truncated form of ER β devoid of the steroid binding domain [20,21]. The MCF-7 and MDA-MB231 cell lines were obtained from the NCI Frederick Cancer Research Facility. The T47D mammary ductal carcinoma cell line is ER α positive and expresses a moderate level of ER β . The TTU-1 mammary ductal carcinoma cell line is ER α negative and the ER β status is unknown [22]. T47D and TTU-1 cell lines were a gift from Dr. Shawn Holt (Department of Pathology, Virginia Commonwealth University, Richmond, VA).

Cytotoxicity assays

Tumor cells (1x10⁴/well) were cultured in 96-well plates in the presence of 17 α -AED (3 – 60 μ M), Custom Steroid Synthesis, Voorhees, NJ) or vehicle (PEG100:ethanol v/v) for 48 h and the level of released lactate dehydrogenase (LDH) was quantified using a LDH-Cytotoxicity Assay Kit II (BioVision, Mountain View, CA). The percentage of cytotoxicity was measured according to the supplied protocol. All culture conditions were performed in triplicate.

Clonogenic assays

Cells were seeded into 6-well cluster plates (250 – 1000 cells/well) and were allowed to adhere for 8 h. 17 α -AED or vehicle was added in triplicate at the indicated doses (1- 20 μ M final). After 48 h of treatment, medium was replaced with drug-free culture medium. In combination experiments, cells were treated with 17 α -AED for 24 h; then exposed to radiation (0.5 – 2.0 Gy) at a rate of 3.90 Gy/min; and cultured for an additional 24h after which media was replaced with drug-free medium. Cells were cultured for an additional 8 – 12 d; rinsed with PBS; fixed with methanol; and colonies were stained with 0.5 % crystal violet. Colonies containing > 50 cells were enumerated; the surviving fraction was calculated; and data was normalized to vehicle treated controls.

Transient transfection and 17 α -AED treatment

MCF-7 cells were seeded into 60 mm dishes and incubated overnight followed by transfection with 4 μ g of plasmid DNA expressing dominant-negative eIF2 α S51A (DN-eIF2 α) or wild type eIF2 α (wt-eIF2 α , gifts from Dr. Constantinos Koumenis, University of Pennsylvania) using Metafectene Pro (Biontex, Martinsried, Germany). After 48h, cells were treated with 17 α -AED (10 μ M) or vehicle for 15 - 48h and then assessed for LC3-cleavage; levels of CHOP or cell death by trypan blue exclusion as indicated.

Immunoblotting

Immunoblotting was performed using whole cell lysates as previously described [18]. Briefly, cells were incubated with 17 α -AED (0 – 20 μ M, final) or vehicle for 15 - 48h, after which lysates were loaded on SDS/PAGE gels and transferred to nitrocellulose membranes. The membranes were incubated overnight with primary antibodies followed by incubation with a horseradish peroxidase conjugated secondary antibody (Rockland Immunochemicals, Gilbertsville, PA). Immuno-reactive bands were visualized using chemiluminescence (SuperSignal, Pierce Chemicals, Rockford, IL). The membranes were re-blotted with a mouse anti- β -actin mAb (Sigma-Aldrich, St. Louis, MO) and used as a loading control. The following primary Abs were used to detect their respective proteins and cleavage products: caspase -3, -8, -9 and PARP were from Santa Cruz Biotechnology (Santa Cruz, CA); LC3 (Novus Biologicals, Littleton, CO); total eIF2 α or phospho-specific (Ser51) eIF2 α (Cell Signaling Technology, Beverly, MA); and CCAAT/enhancer-binding protein homologous protein (CHOP, BioLegend, San Diego, CA).

Detection of acidic vesicular organelles

Acidic vesicular organelles were detected in cells by staining with acridine orange as previously described [18]. Cells were seeded into 6-well plates and cultured in the presence of vehicle or 10 - 20 μ M of 17 α -AED for 72h. Select cultures were supplemented with 3-methyladenine (10 mM, 3-MA, Sigma-Aldrich), an inhibitor of class III phosphoinositol-3-kinase

[15]. Acridine orange (1.0 μ g/ml, Sigma-Aldrich) was added to the cultures for the last 15 min. Total cells were collected and analyzed by flow cytometry using a FACSCanto II (BD Biosciences, San Jose, CA) and cells containing AVOs were identified as double positive cells in the Q2 quadrant of FL1, FL3 histograms.

Statistics

Statistical analysis was performed using a one way analysis of variance test and mean values $\pm$ the standard error of the mean are shown. Differences were considered to be significant when the calculated p value was less than 0.05. SigmaPlot, version 11 (Systat Software, Inc., San Jose, CA) was used for regression analysis of the clonogenic data. The Chou-Talalay method was used to determine the nature of the interaction between 17 α -AED and radiation by calculating combination index (CI) values using CalcuSyn software (Biosoft, Cambridge, UK) [23].

Results

Treatment with 17 α -AED induces cell death of human breast cancer cells

The cytotoxic effects of 17 α -AED were evaluated on MCF-7,

MDA-MB231, T47D and TTU-1 human breast tumor cells which were either ER α positive or negative and varied on the level and functional status of ER β . Cells were treated with titrated concentrations of 17 α -AED (3 – 60 μ M) and cell viability was assessed in short-term (48 h) LDH release assays. The results shown in **Figure 1** indicate that the LD50 for 17 α -AED on the cells tested is between 8 - 15 μ M, with the MCF-7 cells being the most sensitive (LD50 ~ 8.0 μ M). Similar results were obtained using short-term, trypan blue exclusion viability assays (data not shown). Next, we assessed the irreversible anti-tumor effects on breast tumor cell survival after a brief exposure to 17 α -AED using the more sensitive clonogenic assay. MCF-7, MDA-MB231, T47D and TTU-1 cells were treated with various concentrations of the steroid for 48 h and then cultured in drug-free medium for >1 week and the surviving fractions were calculated. The results in **Figure 2** show increased cell sensitivity (LD50 = 3–10 μ M), indicating that 17 α -AED induced additional damage manifested over a longer period of time. These results demonstrate that 17 α -AED induces a significant level of cell death in a concentration dependent fashion in the breast tumor cell lines tested regardless of ER α /ER β steroid signaling status, suggesting that anti-tumor activity is independent of the ER.

Figure 2. Exposure of breast tumor cells to 17α -AED reduces cell survival.

In clonogenic assays, MCF-7, MDA-MB231, TTU-1 and T47D cells were exposed to titrated concentrations of 17α -AED or vehicle for 48 h; then cultured in drug-free medium; and surviving colonies were enumerated. Each experiment was conducted two additional times and yielded similar results.

17α-AED induces autophagy in breast cancer cells in the absence of apoptosis

We assessed the activation of type I and type II programmed cell death pathways in breast tumor cells treated with 17α-AED. MCF-7 cells were exposed to increasing concentrations (0–10 μM) of 17α-AED for 48 h and were analyzed for biochemical markers for the induction of apoptosis and autophagy. Proteolytic processing of initiator caspases-8 and -9; and effector caspase-3 was used to assess the induction of apoptosis [24,25]. Increased conversion of LC3-I (18 kDa) to LC3-II (16 kDa) was used as a marker for autophagy [26]. The results shown in Figure 3a indicate that LC3 processing was augmented in correlation with increasing concentrations of 17α-AED, as indicated by an increased level of LC3-II and a corresponding reduction of LC3-I in treated MCF-7 cells. In contrast, there was no apparent activation of caspases -3, -8, or -9 with the concentrations tested. Similar experiments were conducted with T47D, TTU-1 and MDA-MB231 breast tumor

cells in which apoptosis was assessed by caspase-3 cleavage and PARP processing and autophagy was detected by LC3 conversion. As shown in Figure 3b, treatment of these cells with 20 μM (~ LD-50 as determined in 48 h cytotoxicity assays) of 17α-AED for 48h induced autophagy as evident by LC3 conversion without the activation of apoptosis as indicated by the absence of caspase-3 and PARP cleavage. As a positive control for the induction of apoptosis, U937 myeloma cells treated with 17α-AED were included [17].

To provide further evidence for 17α-AED induced autophagy in breast tumor cells, we analyzed steroid treated MCF-7 and MDA-MB231 cells for the presence of AVOs which is a late event in autophagy [27]. A pilot time course study demonstrated that MCF-7 cells treated for 72 h with 17α-AED(10 μM) was optimal for the detection of intracellular AVOs (data not shown). A significant level of AVO formation of 21.6% was readily detected in treated MCF-7 and MDA-MB231 cells (10μM and 20μM 17α-AED, respectively) but not in vehicle treated cells

Figure 3. Induction of autophagy in the absence of apoptosis in 17α-AED treated breast cancer cells.

a) MCF-7 cells were exposed to vehicle or escalating concentrations (0 – 10 μM) of 17α-AED for 48 h. Immunoblotting was performed for total caspase -3, -8 and -9 and LC3.

b) T47D, TTU-1 and MDA-MB231 were treated with 20 μM 17α-AED for 48 h and cell lysates were immunoblotted for LC-3 conversion and cleavage of caspase-3 and PARP. U937 cells treated with 17α-AED were used as a positive control for caspase-3, -8 and -9 and PARP activation. Independent repetitions of this experiment yielded similar results.

(**Figure 4a**). The addition of the class III phosphoinositol-3-kinase inhibitor, 3-MA (1mM), to MCF-7 or MDA-MB231 cell cultures treated with 17α-AED reduced the presence of AVOs to baseline levels (**Figure 4a**). Representative histograms used for the detection of AVOs in MCF-7 cells are shown in **Figure 4b**. These findings strongly indicate that 17α-AED treatment induces autophagic cell death in human breast cancer cells.

eIF2α signaling in human breast cancer cells treated with 17α-AED

eIF2α activation results in the transient repression of translation with the exception of specific endoplasmic reticulum-stress associated mRNAs such as CHOP and can induce autophagy in cells [28]. We investigated the activation status of eIF2α in MCF-7 and MDA-MB231 cells treated with 17α-AED (10 and 20 μM, respectively). As shown in **Figure 5a**, there is an increased level of eIF2α phosphorylation in these cells after 24 h of 17α-AED exposure while there were no noticeable changes in the total level of eIF2α. These results suggest

eIF2α activation may be involved with 17α-AED induced autophagic cell death in breast cancer cells.

To establish a connection between eIF2α phosphorylation and the anti-tumor effects of 17α-AED on breast tumor cells, we disrupted eIF2α signaling in MCF-7 cells by transient transfection with a DN-eIF2α construct [29]. As shown in **Figure 5b**, cells transfected with DN-eIF2α have reduced protein levels of CHOP after 17α-AED treatment as compared to transfected control cells, confirming down-modulation of eIF2α signaling. Moreover, 17α-AED induced LC3 cleavage and cell death was attenuated in MCF-7 cells with reduced eIF2α activity as compared to transfection control cells exposed to the drug (**Figure 5b** and **5c**). These results implicate the involvement of eIF2α signaling in 17α-AED induced autophagic cell death in human breast cancer cells.

17α-AED potentiates the cytotoxic effects of radiation on human breast cancer cells

We assessed the combined effects of 17α-AED treatment and

Figure 4. AVO formation in breast cancer cells treated with 17α-AED.

a) MCF-7 and MDA-MB231 cells were treated with 17α-AED (10 μM and 20 mM, respectively); 17α-AED and 3-MA (10 mM); or vehicle for 3 days and the percentage of cells containing AVOs was evaluated. Mean values of 3 independent experiments are shown. $P < 0.005$. **b)** Representative histograms of MCF-7 cells treated with vehicle (left); 10 μM of 17α-AED (middle); or 10 μM of 17α-AED in the presence of 10 mM 3-MA (right) are shown. Annotated numbers indicate the percentage of cells positive for AVOs (quadrant Q2).

Figure 5. eIF2α signaling in 17α-AED treated breast tumor cells.

a) MCF-7 and MDA-MB231 cells were exposed to 17α-AED (17α, 10 μM and 20 μM, respectively) or vehicle (veh) for 24 h. Immunoblotting was performed to detect the phosphorylated form of eIF2α (p-eIF2α) or total eIF2α (t-eIF2α). **b)** MCF-7 cells were transfected with a DN-eIF2α or wild-type eIF2α (wt-eIF2α, control) plasmid construct and 48 h later cells were treated with 17α-AED (17α, 10 μM) or vehicle (veh). After 15 h of treatment, immunoblotting for CHOP was performed and, after 48 h of drug treatment, LC3 conversion was assessed. **c)** A fraction of the transfected MCF-7 cells were exposed to vehicle or 17α-AED (17α, 10 μM) for 48 h and cell viability was evaluated. The results indicate that disruption of eIF2α signaling reduces 17α-AED induced cell death. ($p < 0.01$). Representative results of 2 independent experiments are shown.

Figure 6. 17α -AED enhances radiation cytotoxicity on breast cancer cells.

MCF-7 and MDA-MB231 cells were exposed to escalating, fixed dose ratios of 17α -AED (17α) or vehicle for 48 h and radiation (rad) as indicated and survival was assessed in clonogenic assays. *p < 0.02, **p<0.002. Similar results were obtained upon replication.

radiation on breast tumor cell survival to determine if the steroid can enhance the anti-tumor activity of a conventional form of breast cancer therapy. MCF-7 and MDA-MB231 cells were exposed to escalating concentrations of 17α-AED for 48 h and, midway through drug treatment, cells were subjected to increasing doses of radiation. The results shown in **Figure 6** indicate that the presence of 17α-AED significantly enhances the cytotoxic activity of radiation on the tumor cells. To establish the nature of the combined effects, CI values were calculated based upon normalized colony formation where a CI value <1 indicates synergy. As shown in **Table 1**, there is synergy between the two treatments in the fixed dose ratios tested which is readily appreciable in the MCF-7 cells and MDA-MB231 cells exposed to the higher combinations, as compared to the single treatment groups.

Discussion

We have previously demonstrated that 17α-AED inhibits the proliferation of human breast cancer cells; however, the cytotoxic activity of 17α-AED and the mechanisms involved in the anti-tumor activity have not been investigated [9]. Initial studies evaluated both short-term and long-term

cytotoxicity of 17α-AED on several human breast cancer cells. The results of these studies were similar and revealed that the LC50 of 17α-AED was less than 15.0μM on the tumor cell lines tested with MCF-7 cell being the most sensitive. Moreover, responsiveness to 17α-AED is most likely not mediated through

Table 1. 17α-AED and radiation synergize to enhance breast tumor cell death^a

Cell line	17α-AED (μM)	Radiation (Gy)	Fa	CI
MCF-7	1.0	0.5	0.62	0.490
	2.0	1.0	0.70	0.680
	3.0	1.5	0.81	0.559
MDA-MB231	5.0	1.0	0.60	0.905
	7.5	1.5	0.81	0.777
	10.0	2.0	0.88	0.778

^a Medium dose analysis was conducted on the clonogenic survival data from **Figure 6** using the CalcuSyn program and combination index (CI) values were calculated. A CI values <1.00 indicates synergy, CI =1 is additive, and CI >1 indicates antagonism. Fa indicates the fraction of cells affected.

ER signaling since the steroid induced cell death in both ER α +, ER α - breast tumors and MBA-MDA231 cells which lack steroid induced, ER β signaling [19,21]. This is of importance because a majority of treatment approaches for breast cancer involve targeting this hormone receptor. Likewise, the role of the tumor suppressor protein p53 can be considered negligible since both p53 wild-type (MCF-7) and p53 mutant (MDA-MB231 and T47D) cell lines were sensitive to 17 α -AED treatment [30]. Aspinnall et al. [31] recently reported that 5-androstene 3 β ,17 α diol (the epimer of 17 α -AED) stimulates the proliferation of human breast tumor cells through an ER mediated mechanism. This is noteworthy since the 5-androstenediols epimers are chemically identical, only differing in the orientation of the hydroxyl group on C-17, however this results in major different biological effects and underscores the strict structure-activity relationship of these steroids [32].

Subsequent studies investigated the activation of type I (apoptosis) and type II (autophagy) programmed cell death pathways in breast tumor cells in response to 17 α -AED treatment. MCF-7 cells exposed to escalating concentrations of 17 α -AED were positive for LC3 cleavage, a biochemical marker for autophagy [26]. In addition, a significant percentage of breast cancer cells contained acidic autolysosomes after androstene treatment. In contrast, no increase in the degree of the activation of initiator caspases-8 and 9 or of the effector caspase-3 was detected in 17 α -AED treated MCF-7 cells. Similar results were obtained when MDA-MB231, T47D and T47D breast cancer cells were treated with the steroid. Collectively, these results indicate that 17 α -AED, when used at pharmacologically relevant concentrations, induces autophagic cell death in human breast tumor cells, regardless of ER α status.

Phosphorylation of eIF2 α results in the general inhibition of protein synthesis under a variety of stressful conditions such as nutrient starvation or the accumulation of unfolded proteins in the endoplasmic reticulum and may lead to apoptosis or autophagy [28,33]. 17 α -AED treatment of MCF-7 and MDA-MB231 cells resulted in increased levels of eIF2 α phosphorylation, suggesting an involvement in the biological effects of the steroid. Down modulation of eIF2 α signaling resulted in reduced autophagy and cell death in MCF-7 breast cancer cells exposed to 17 α -AED. This indicates that eIF2 α activity may play a role in the anti-tumor activity of 17 α -AED on breast tumors.

It has been estimated that the risk of breast cancer recurrence is >20% after conservative surgery and loco-regional radiotherapy is routinely used in an attempt to eradicate residual disease [34]. However, in addition to the discomfort there may be harmful consequences that accompany radiation treatment; therefore, a therapy that would increase the efficacy of radiation and allow for a significant reduction to exposure levels would be beneficial. In the last series of experiments, we demonstrated that treatment of breast tumor cells with 17 α -AED synergistically enhances the anti-tumor effects of radiation. Exposure of MCF-7 cells

to radiation has been reported to promote autophagy which is generally considered a cytoprotective response [35]. Kim et al. [36] recently reported that radiation induces autophagy in MCF-7 cells by the activation of the endoplasmic reticulum response and protein kinase-like endoplasmic reticulum kinase/eIF2 α signaling and that the treatment with tunicamycin, a well known inducer of endoplasmic reticulum stress, greatly enhances the radiosensitivity of the MCF-7 cells. It is tempting to speculate, that in our studies of combination 17 α -AED and radiation treatment of breast tumor cells, the co-activation of endoplasmic reticulum stress and eIF2 α signaling overrides the cytoprotective aspect of autophagy to potentiate cancer cell death.

Conclusions

Our findings demonstrate that in vitro treatment with 17 α -AED induces autophagic cell death in human breast tumor cells which appears to be independent of ER α / β . Additionally, the cytotoxic activity of this steroid on breast cancer cells is dependent, at least in part, to eIF2 α signaling. Finally, we have shown that 17 α -AED either enhance or synergistically interacts with radiation to potentiate breast tumor cell death. It is possible that 17 α -AED may have therapeutic value in the treatment of breast tumors as a single agent or an adjuvant.

List of abbreviations

17 α -AED, 5-androstene 3 β ,17 diol,
AVOs: acidic vesicular organelles,
CHOP, CCAAT: enhancer-binding protein homologous protein,
CI: combination index,
DHEA: dehydroepiandrosterone,
DN: dominant-negative,
eIF2 α : eukaryotic translation initiation factor 2,
ER: estrogen receptor,
Her-2/neu: human epidermal growth factor receptor 2,
LC3: microtubule-associated protein-light chain 3,
3-MA: 3-methyladenine
PARP: poly (ADP-ribose) polymerase,
wt: wild type.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

MRG designed the study; analyzed and interpreted the data; conducted the combination radiation and drug treatment experiments; and drafted the manuscript. WJ and TP executed the immunoblotting; eIF2 α signaling disruption experiments; cytotoxicity and clonogenic assays; and were involved with data and image acquisition. RML conceptualized and co-designed the study; interpreted the experimental results; and critically reviewed and approved the manuscript.

Acknowledgements

The authors thank Dr. Constantinos Koumenis (University of Pennsylvania. School of Medicine, Philadelphia, PA) for the eIF2 α constructs and the generous support from the James and Martha Betts Foundation and from Ginny and Charles Crone (Williamsburg, VA). This work was supported in part

by a grant from the MCV Medical Center A.D. Williams Trust Funds (M.R.G.) and the SCDR Cancer Research Fund (R.M.L.).

Publication history

Editor-1: Ivan Garcia-Bassets, University of California San Diego, USA.

Editor-2: Iris J Edwards, Wake Forest University, USA.

EIC: G.J. Peters, VU University Medical Center, Netherlands.

Received: 14-May-2012 Revised: 21-July-2012

Re-revised: 18-Aug-2012 Re-revised by EIC: 07-Sep-2012

Accepted: 13-Sep-2012 Published: 24-Sep-2012

References

1. American Cancer Society. (2009) **Breast Cancer Facts and Figures 2007 – 2008**. Atlanta: America Cancer Society, Inc.
2. Johnston SR: **Enhancing the efficacy of hormonal agents with selected targeted agents**. *Clin Breast Cancer* 2009, **9 Suppl 1**:S28-36. | [Article](#) | [PubMed](#)
3. Hudis CA: **Current status and future directions in breast cancer therapy**. *Clin Breast Cancer* 2003, **4 Suppl 2**:S70-75. | [Article](#) | [PubMed](#)
4. Slamon DJ: **Proto-oncogenes and human cancers**. *N Engl J Med* 1987, **317**:955-957. | [Article](#) | [PubMed](#)
5. Dean-Colomb W, Esteva FJ: **Her2-positive breast cancer: herceptin and beyond**. *Eur J Cancer* 2008, **44**:2806-2812. | [Article](#) | [PubMed](#)
6. Schwartz AG, Pashko L, Whitcomb JM: **Inhibition of tumor development by dehydroepiandrosterone and related steroids**. *Toxicol Pathol* 1986, **14**:357-362. | [Article](#) | [PubMed](#)
7. Couillard S, Labrie C, Belanger A, Candas B, Pouliot F, Labrie F: **Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts**. *J Natl Cancer Inst* 1998, **90**:772-778. | [Article](#) | [PubMed](#)
8. Loria RM: **Immune up-regulation and tumor apoptosis by androstene steroids**. *Steroids* 2002, **67**:953-966. | [Article](#) | [PubMed](#)
9. Huynh PN, Carter WH, Jr., Loria RM: **17 alpha androstenediol inhibition of breast tumor cell proliferation in estrogen receptor-positive and -negative cell lines**. *Cancer Detect Prev* 2000, **24**:435-444. | [PubMed](#)
10. Kim J, Klionsky DJ: **Autophagy, cytoplasm-to-vacuole targeting pathway, and pexophagy in yeast and mammalian cells**. *Annu Rev Biochem* 2000, **69**:303-342. | [Article](#) | [PubMed](#)
11. Levine B, Yuan J: **Autophagy in cell death: an innocent convict?** *J Clin Invest* 2005, **115**:2679-2688. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
12. Shintani T, Klionsky DJ: **Autophagy in health and disease: a double-edged sword**. *Science* 2004, **306**:990-995. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
13. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B: **Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer**. *Autophagy* 2010, **6**:322-329. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
14. Yang YP, Liang ZQ, Gu ZL, Qin ZH: **Molecular mechanism and regulation of autophagy**. *Acta Pharmacol Sin* 2005, **26**:1421-1434. | [Article](#) | [PubMed](#)
15. Petiot A, Ogier-Denis E, Blommaert EF, Meijer AJ, Codogno P: **Distinct classes of phosphatidylinositol 3'-kinases are involved in signaling pathways that control macroautophagy in HT-29 cells**. *J Biol Chem* 2000, **275**:992-998. | [Article](#) | [PubMed](#)
16. Huynh PN, Loria RM: **Contrasting effects of alpha- and beta-androstenediol on oncogenic myeloid cell lines in vitro**. *J Leukoc Biol* 1997, **62**:258-267. | [Article](#) | [PubMed](#)
17. Graf MR, Jia W, Loria RM: **The neuro-steroid, 3beta androstene 17alpha diol exhibits potent cytotoxic effects on human malignant glioma and lymphoma cells through different programmed cell death pathways**. *Br J Cancer* 2007, **97**:619-627. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
18. Graf MR, Jia W, Johnson RS, Dent P, Mitchell C, Loria RM: **Autophagy and the functional roles of Atg5 and beclin-1 in the anti-tumor effects of 3beta androstene 17alpha diol neuro-steroid on malignant glioma cells**. *J Steroid Biochem Mol Biol* 2009, **115**:137-145. | [Article](#) | [PubMed](#)
19. Jia W, Loria RM, Park MA, Yacoub A, Dent P, Graf MR: **The neuro-steroid, 5-androstene 3beta,17alpha diol; induces endoplasmic reticulum stress and autophagy through PERK/eIF2alpha signaling in malignant glioma cells and transformed fibroblasts**. *Int J Biochem Cell Biol* 2010, **42**:2019-2029. | [Article](#) | [PubMed](#)
20. Wang S, Aarts JM, Evers NM, Peijnenburg AA, Rietjens IM, Bovee TF: **Proliferation assays for estrogenicity testing with high predictive value for the in vivo uterotrophic effect**. *J Steroid Biochem Mol Biol* 2012, **128**:98-106. | [Article](#) | [PubMed](#)
21. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F: **ER beta inhibits proliferation and invasion of breast cancer cells**. *Endocrinology* 2001, **142**:4120-4130. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
22. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, Kodagoda D, Stasny V, Cunningham HT, Wistuba II, Tomlinson G, Tonk V, Ashfaq R, Leitch AM, Minna JD, Shay JW: **Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer**. *Int J Cancer* 1998, **78**:766-774. | [Article](#) | [PubMed](#)
23. Chou TC, Talalay P: **Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors**. *Adv Enzyme Regul* 1984, **22**:27-55. | [Article](#) | [PubMed](#)
24. Nunez G, Benedict MA, Hu Y, Inohara N: **Caspases: the proteases of the apoptotic pathway**. *Oncogene* 1998, **17**:3237-3245. | [Article](#) | [PubMed](#)
25. Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM: **Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant**. *J Biol Chem* 1998, **273**:33533-33539. | [Article](#) | [PubMed](#)
26. Mizushima N: **Methods for monitoring autophagy**. *Int J Biochem Cell Biol* 2004, **36**:2491-2502. | [Article](#) | [PubMed](#)
27. Paglin S, Hollister T, Delohery T, Hackett N, McMahon M, Sphicas E, Domingo D, Yahalom J: **A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles**. *Cancer Res* 2001, **61**:439-444. | [Article](#) | [PubMed](#)
28. Schroder M: **Endoplasmic reticulum stress responses**. *Cell Mol Life Sci* 2008, **65**:862-894. | [Article](#) | [PubMed](#)
29. Koumenis C, Naczki C, Koritzinsky M, Rastani S, Diehl A, Sonenberg N, Koromilas A, Wouters BG: **Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha**. *Mol Cell Biol* 2002, **22**:7405-7416. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
30. Nieves-Neira W, Pommier Y: **Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways**. *Int J Cancer* 1999, **82**:396-404. | [Article](#) | [PubMed](#)
31. Aspinall SR, Stamp S, Davison A, Shenton BK, Lennard TW: **The proliferative effects of 5-androstene-3 beta,17 beta-diol and 5 alpha-dihydrotestosterone on cell cycle analysis and cell proliferation in MCF7, T47D and MDAMB231 breast cancer cell lines**. *J Steroid Biochem Mol Biol* 2004, **88**:37-51. | [Article](#) | [PubMed](#)
32. Graf MR, Jia W, Lewbart ML, Loria RM: **The anti-tumor effects of androstene steroids exhibit a strict structure-activity relationship dependent upon the orientation of the hydroxyl group on carbon-17**. *Chem Biol Drug Des* 2009, **74**:625-629. | [Article](#) | [PubMed](#)
33. Py BF, Boyce M, Yuan J: **A critical role of eEF-2K in mediating autophagy in response to multiple cellular stresses**. *Autophagy* 2009, **5**:393-396. | [Article](#) | [PubMed Abstract](#) | [PubMed Full Text](#)
34. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y: **Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials**. *Lancet* 2005, **366**:2087-2106. | [Article](#) | [PubMed](#)

35. Chaachouay H, Ohneseit P, Toulany M, Kehlbach R, Multhoff G, Rode-
mann HP: **Autophagy contributes to resistance of tumor cells to ion-
izing radiation.** *Radiother Oncol* 2011, **99**:287-292. | [Article](#) | [PubMed](#)
Abstract | [PubMed Full Text](#)
36. Kim KW, Moretti L, Mitchell LR, Jung DK, Lu B: **Endoplasmic reticulum
stress mediates radiation-induced autophagy by perk-eIF2alpha in
caspase-3/7-deficient cells.** *Oncogene* 2010, **29**:3241-3251. | [Article](#) |
[PubMed Abstract](#) | [PubMed Full Text](#)

Citation:

Graf MR, Jia W, Powell T and Loria RM: **5-androstene
3 β ,17 α diol induces autophagic cell death of human
breast cancer cells and enhances radiation cytotoxicity.**
Journal of Cancer Therapeutics and Research 2012, **1**:25.
<http://dx.doi.org/10.7243/2049-7962-1-25>